Clinical and histopathological features of adult patients with dermatomyositis and melanoma differentiation associated‐5 autoantibody seropositivity status, as determined by commercially available testing: a retrospective, single‐institution comparative cohort study

Autor: Shakshouk, H., Deschaine, M. A., Wetter, D. A., Drage, L. A., Ernste, F. C., Lehman, J. S.
Předmět:
Zdroj: Clinical & Experimental Dermatology; Feb2022, Vol. 47 Issue 2, p282-288, 7p, 2 Color Photographs, 2 Charts
Abstrakt: Summary: Background: Although melanoma differentiation associated (MDA)‐5 autoantibodies have been widely explored in dermatomyositis (DM), most studies have relied on MDA‐5 autoantibody testing performed in research settings, rather than the now‐available commercial laboratory tests. Aim: To characterize the clinical and histopathological data in patients with DM and circulating MDA‐5 autoantibodies, as defined by commercially available testing. Methods: This was a retrospective review of patients with DM who underwent MDA‐5 antibody testing. All available skin biopsy slides were reviewed. Results: Cutaneous features more prevalent in MDA‐5‐positive DM included Raynaud phenomenon (RP) (P < 0.001), cutaneous ulcerations (P = 0.01), mechanic hands (P < 0.02), palmar papules (P < 0.01), oral ulcers (P = 0.024) and alopecia (P = 0.03). Joint and pulmonary involvement were more common in patients with MDA‐5‐positive DM (both P < 0.001) as was dysphagia (P < 0.01). Myopathy (P = 0.4) and malignancy (P = 0.34) were not statistically different between the cohorts. Vasculopathy was more common in MDA‐5‐positive DM (P < 0.01), while spongiosis was less common (P < 0.02). Conclusion: This study not only confirms some known associations between disease manifestations and MDA‐5 autoantibody status, as determined by commercially available tests, but also identifies new associations, including RP and dysphagia. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje